Skip to navigation Skip to content

Research Study: MS Biomarkers


Treatment mode of action: n/a
Number of Subjects: 1000
Medication: n/a
Location: California
Institutions: Sutter Health Contact Information
Gregory Tranah, PhD




The Sutter Health MS genetic study is recruiting people with MS from ten sites across its healthcare system to participate in a DNA sequencing study. The main objectives are to identify biomarkers of disease subtype, progression, and treatment response. The study is open to current and new patients and involves a clinic visit for consenting, blood draw, EDDS assessment, and a questionnaire. Data from electronic health records will be accessed to identify clinical features related to genetic factors. Strong security measures and study governance ensure patient privacy and anonymity. The study is representative of the racial/ethnic, age, sex, and disease diversity of Sutter Health patients.

Participating sites include:
Sutter East Bay Medical Foundation (Neurology): 2850 Telegraph Ave, Berkeley, CA 94705
Palo Alto Medical Foundation: Palo Alto Center, 795 El Camino Real Lee Building, Level 3, Palo Alto, CA 94301
Palo Alto Medical Foundation: Mountain View Center, 701 E. El Camino Real North Wing, 2nd Floor, Mountain View, CA 94040
Santa Cruz Neurology, 1661 Soquel Drive, Suite D, Santa Cruz, CA, 95065
Sutter Medical Foundation, 2800 L Street, #500, Sacramento, CA 95816


© 2022 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.